Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial

NCT07191977 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07191977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07191977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
December 31, 2029
Enrollment
41 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamour cell cancer